Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

CHOK1 cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) ADC Antibody (1) Apelin Receptor (APJ) (1) Biochemical Assay Reagents (1) Claudin (1) CRFR (1) Drug Metabolite (1) EGFR (1) FLT3 (1) G2A (GPR132) (1) GCGR (3) GLP Receptor (4) GnRH Receptor (1) Histone Acetyltransferase (1) Interleukin Related (1) Isotope-Labeled Compounds (1) mAChR (1) Neurokinin Receptor (1) Neurotensin Receptor (1) Prostaglandin Receptor (1) Sodium Channel (1) Somatostatin Receptor (2) TGF-beta/Smad (1) TNF Receptor (1) Tyrosinase (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (8) Neurological Disease (6)

By Targets:

5-HT Receptor (2)

ADC Antibody (1)

Apelin Receptor (APJ) (1)

Biochemical Assay Reagents (1)

Claudin (1)

CRFR (1)

Drug Metabolite (1)

EGFR (1)

FLT3 (1)

G2A (GPR132) (1)

GCGR (3)

GLP Receptor (4)

GnRH Receptor (1)

Histone Acetyltransferase (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

mAChR (1)

Neurokinin Receptor (1)

Neurotensin Receptor (1)

Prostaglandin Receptor (1)

Sodium Channel (1)

Somatostatin Receptor (2)

TGF-beta/Smad (1)

TNF Receptor (1)

Tyrosinase (1)

By Research Areas:

Cancer (6)

Cardiovascular Disease (2)

Endocrinology (1)

Inflammation/Immunology (4)

Metabolic Disease (8)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Choline Kinase Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P990006

Duvakitug TEV-48574; SAR-447189; TEV-574	TNF Receptor	Inflammation/Immunology
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .

HY-108003

MM 07	Apelin Receptor (APJ)	Cardiovascular Disease
MM 07 is a biased apelin receptor agonist, with a K_D of 300 nM in CHO-K1 cells and a K_D of 172 nM in human heart.

HY-161247

5-HT2A antagonist 2	5-HT Receptor	Metabolic Disease
5HT2A antagonist 2 is an orally active, selective antagonist for 5HT_2A with IC₅₀ of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .

HY-P99870

Eblasakimab ASLAN004; CSL-334; MK-6105	Interleukin Related	Others
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .

HY-P990009

Nisevokitug NIS-793	TGF-beta/Smad	Cancer
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .

HY-123335A

L-796778 acetate	Somatostatin Receptor	Neurological Disease
L-796778 acetate is a selective agonist of the sst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796778 acetate is a partial agonist that inhibits Forskolin (HY-15371)-stimulated cAMP production with an IC₅₀ value of 18 nM. L-796778 acetate has anticonvulsant effect .

HY-P3789

Prolactin-Releasing Peptide (12-31), rat	GnRH Receptor	Metabolic Disease
Prolactin-Releasing Peptide (12-31), rat is a fragment of the prolactin releasing peptide (PrRP). Prolactin-Releasing Peptide (12-31), rat shows high affinity for GPR10 receptors. Prolactin-Releasing Peptide (12-31), stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor .

HY-136895

AZ12672857	Prostaglandin Receptor	Cancer
AZ12672857 is an orally active inhibitor of EphB4 (IC₅₀=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC₅₀=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC₅₀=9 nM) .

HY-132225

SB 206553	5-HT Receptor	Inflammation/Immunology
SB 206553 is a 5-HT_2C inverse agonist. SB 206553 can attenuate methamphetamine-seeking in rats. SB 206553 has activity for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells expressing human recombinant 5-HT2 receptors with pKi values of 5.6 nM (5-HT_2A), 7.7 nM (5-HT_2B) and 7.8 nM (5-HT_2C), respectively. SB 206553 can be used for the research of psychostimulant abuse disorders .

HY-P99888

Pimurutamab	EGFR	Others
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .

HY-123335

L-796778	Somatostatin Receptor	Others
L-796778 is an agonist of the hsst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796778 is a partial agonist that inhibits forskolin (HY-15371)-stimulated cAMP production with an IC₅₀ value of 18 nM .

HY-117617

CAY10669	Histone Acetyltransferase	Cancer
CAY10669 (compound 6d) is an anacardic acid (HY-N2020) derivative that inhibits histone acetyltransferase PCAF with an IC₅₀ of 662 μM . CAY10669 enhances the SAHA-induced acetylation in HEPG2 cells, exhibits cytotoxicity in zebrafish embryo, promotes transgene expression in CHO-K1 cells .

HY-P991114

Adezkibart	FLT3	Inflammation/Immunology
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-171854

SB-583355	G2A (GPR132)	Neurological Disease Inflammation/Immunology
SB-583355 (Compound 56) is a potent G2A antagonist. SB-583355 can be prepared by a Suzuki reaction between 4-methoxyphenyl boronic acid and 3-bromo-4-hydroxybenzoic acid following the conditions followed by an amide coupling reaction. SB-583355 blocks the activation of G2A mediated either by 9-HOPE or T-10148 in human G2A expressing CHO-K1 cells. SB-583355 can be studied in research for inflammation, myeloid leukemia, and neuropathic pain .

HY-P4146B

Survodutide sodium BI 456906 sodium	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) sodium is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide sodium, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide sodium has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-137749A

MANT-dADP trisodium 2'-Deoxy-3'-MANT-ADP trisodium	Biochemical Assay Reagents	Others
MANT-dADP (trisodium) (2'-Deoxy-3'-MANT-ADP (trisodium)) is a fluorescent nucleotide derivative, with an emission maximum of 453 nm upon excitation at 350 nm. MANT-dADP (trisodium) can decrease inositol phoshate formation in CHO-K1 cells that express human purinergic P2Y₁₂ receptor. MANT-dADP (trisodium) can be studied in research on the interaction between cardiac troponin I and myofibrils .

HY-124104

Aldicarb sulfoxide	Drug Metabolite	Cardiovascular Disease Metabolic Disease
Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC₅₀ of 10 μM for both in zebrafish .

HY-100962A

AG 99 Tyrphostin 46; Tyrphostin AG 99	Tyrosinase	Cancer
AG 99 (Tyrphostin 46), a tyrphostin derivative, is a tyrosine kinase inhibitor that increases sister chromatid exchange frequency in transformed CHO-K1 and primary CHE cells. AG 99 is promising for research of proliferative diseases .

HY-P5872

Jingzhaotoxin XI JZTX-XI	Sodium Channel	Neurological Disease
Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC₅₀ of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC₅₀=1.18±0.2 μM) of Na_v1.5 expressed in Chinese hamster ovary (CHO-K1) cells .

HY-124104S

Aldicarb sulfoxide-d3	Isotope-Labeled Compounds	Metabolic Disease
Aldicarb sulfoxide-d₃ is the deuterium labled Aldicarb sulfoxide (HY-124104). Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC₅₀ of 10 μM for both in zebrafish .

HY-174259

Muscarinic M4 modulator-1	mAChR	Neurological Disease
Muscarinic M4 modulator-1 is a Muscarinic M4 receptor positive allosteric modulator. Muscarinic M4 modulator-1 activates the muscarinic M4 receptor with allosteric potency EC₅₀ s of 14 and 3 Nm in CHO-K1 cells and HEK293 cells. Muscarinic M4 modulator-1 has an antipsychotic-like activity, promising for psychiatric and/or neurological disorders research .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

HY-113513

5-HEPE	Others	Cancer
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

HY-176546

NK3R-IN-2	Neurokinin Receptor	Endocrinology
NK3R-IN-2 is an orally active NK3R inhibitor with an IC₅₀ of 330.50 nM for human NK3R. NK3R-IN-2 can pass through the blood-brain barrier. NK3R-IN-2 has excellent NK3R binding affinity (IC₅₀ = 87.31 nM) in CHO-K1 cells. NK3R-IN-2 effectively inhibits the level of luteinizing hormone (LH). NK3R-IN-2 can be used for research on hormone related conditions .

HY-182645

CRF1 receptor antagonist-2	CRFR	Neurological Disease
CRF1 receptor antagonist-2 is an orally active, blood-brain barrier permeable CRF1 receptor antagonist, with an IC₅₀ of 4 nM in CHO-K1 cell membranes and an IC₅₀ of 7 nM in rat brain cell membranes. CRF1 receptor antagonist-2 exerts anxiolytic effects in swim stress-loaded rats. CRF1 receptor antagonist-2 can be used in studies related to stress-induced anxiety .

HY-W574030

Fmoc-DL-Leu-OH	Neurotensin Receptor	Neurological Disease
Fmoc-DL-Leu-OH acts as a partial agonist of the neurotensin NTS1 receptor (NTS1R) with an EC₅₀ of 215.50 μM. Fmoc-DL-Leu-OH triggers intracellular calcium mobilization, and its activity is blocked by selective NTS1R antagonists. Fmoc-DL-Leu-OH can be used in the research of schizophrenia .

HY-P992316

ATG-022 Antibody	Claudin ADC Antibody	Cancer
ATG-022 Antibody is a humanized monoclonal antibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer .

Cat. No.	Product Name	Target	Research Area